Vismodegib as novel treatment of periocular basal cell carcinoma: A mini review

Research output: Contribution to journalReview articlepeer-review


Basal cell carcinoma (BCC) is the most common cancer in the world. This study aims to review vismodegib treatment in BCC patients. Vismodegib has been approved for the treatment of adults with mBCC, or with laBCC that has recurred after surgery or who are not eligible for surgical procedure nor radiation. Despite all advantages it possesses, this drug still has limitations such as its inevitably occurring side effects of Vismodegib which lead to a significant rate of treatment discontinuation limiting complete drug exposure as described in previous studies. Hence, long-term continuous treatment with Vismodegib might be not feasible for certain group of patients. Vismodegib had become an established treatment option for patients with locally advanced or metastatic BCC in clinical practice.

Original languageEnglish
Pages (from-to)587-595
Number of pages9
JournalSystematic Reviews in Pharmacy
Issue number3
Publication statusPublished - 2020


  • Basal cell carcinoma
  • Treatment
  • Vismodegib


Dive into the research topics of 'Vismodegib as novel treatment of periocular basal cell carcinoma: A mini review'. Together they form a unique fingerprint.

Cite this